Outcomes | Baseline measurements in each cycle (1 time/cycle) | Baseline measurements in each phase of the MC (3 times/cycle) | Pre-sessions | Post-sessions | 24 hours post-sessions | 48 hours post-sessions | 72 hours post-sessions |
Primary outcomes | |||||||
Satisfaction | x | x | x | x | x | ||
Visual Analogue Scale for Fatigue (VAS-F) | x | x | x | x | x | ||
Secondary outcomes | |||||||
Abdominal obesity and anthropometric variables | x | ||||||
Dietary and nutritional monitoring | x | ||||||
Monitoring of PA levels | x | ||||||
Walking endurance (2-MWT) | x | ||||||
Physical self-perception | x | ||||||
Catastrophizing Pain Scale | x | ||||||
Modified Fatigue Impact Scale | x | ||||||
Multiple Sclerosis Quality of Life-54 | x | ||||||
State anxiety and trait anxiety | x | ||||||
Body temperature | x | ||||||
Bioimpedance analysis | x | ||||||
Reproductive hormonal profile | x | ||||||
Inflammatory profiles | x | x* | |||||
Cognitive profiles | x | x* | |||||
Neuromuscular strength, voluntary activation and contractile properties: RFD, MVIC, CAR, MULS | x | x | x | x | x | ||
Functional assessment: spasticity, gait speed, balance, STS, TUG | x | x | x | x | x | ||
Rating of Perceived Exertion | x | x | |||||
Pain: VAS, algometer | x | x | x | x | x | ||
Muscle oxygen saturation | During sessions | ||||||
Lactate | x | x† | |||||
VO2max | During sessions | ||||||
Heart rate variability (HRV) | During sessions | ||||||
Quality of sleep: Karolinska Sleep Diary Questionnaire, actigraphy-based sleep quality, HRV | x | x | x |
*It will be assessed immediately, at 30 min and 2 hours after the end of the session.
†It will be assessed immediately, at 3 min and 30 min after test.
CAR, central activation ratio; MC, menstrual cycle; MULS, maximal upper limb strength; MVIC, maximal voluntary isometric strength of the lower limbs; 2-MWT, 2-Minute Walk Test; PA, physical activity; RFD, rate force development; STS, sit-to-stand; TUG, timed up and go test; VO2max, maximal oxygen consumption.